Is higher income and educational status associated with poorer outcome in patients with Hodgkin's disease?

Abstract:

OBJECTIVES:The aim of the study was to determine the impact of socioeconomic status on relapse-free survival (RFS) in patients with Hodgkin's disease. METHODS:A number of factors were analyzed for their impact on relapse-free and overall survival in Hodgkin's disease using Cox regression. These factors included socioeconomic status (as defined by education and income), different treatment modalities and established clinical risk factors [e.g. age at diagnosis, stage of disease, involvement of three or more lymph nodes, presence or absence of a large mediastinal mass, E stages or elevation of erythrocyte sedimentation rate (ESR)]. The study used an initial sample of 126 patients recruited between 1969 and 1995 and a larger sample of 218 patients (recruited until 2002). Clinical data on disease and treatment characteristics were collected from medical records. RESULTS:In a univariate analysis, the following parameters had impact on RFS: treatment modality (combined treatment resulted in an improved RFS compared with patients treated with chemo- or radiotherapy alone), educational status and income. The 5- and 10-yr relapse-free survival rates were found to increase with decreasing educational level and decreasing average income per month. These results were significant in the initial and total samples and were also significant using multivariate analysis (hazard ratio for highest vs. lowest education group: 5.88; 95% confidence interval 1.87-18.52; for highest vs. lowest income group: 4.36; 95% confidence interval 1.35-14.05). CONCLUSION:Hodgkin's disease appears to be a striking exception from the usual positive correlation between high socioeconomic status and favorable treatment outcome in patients suffering from tumor. It is suggested that future studies on tumor genetics and biology and more detailed analysis of further socioeconomic parameters may be useful in clarifying this observation.

journal_name

Eur J Haematol

authors

Holzner B,Fischhofer M,Kemmler G,Kopp M,Sperner-Unterweger B,Krugmann J,Dirnhofer S,Greil R

doi

10.1111/j.1600-0609.2004.00315.x

subject

Has Abstract

pub_date

2004-11-01 00:00:00

pages

318-24

issue

5

eissn

0902-4441

issn

1600-0609

pii

EJH315

journal_volume

73

pub_type

临床试验,杂志文章,随机对照试验
  • Bone marrow biopsy in Hodgkin's lymphoma.

    abstract::In the study of patients with Hodgkin's lymphoma (HL) the evaluation of bone marrow biopsy (BMB) can be difficult. In this review we analyze the main diagnostic features and the clinical risk factors of BM involvement. Although the role of BMB is criticized by some authors, its value is irreplaceable in the staging of...

    journal_title:European journal of haematology

    pub_type: 杂志文章,评审

    doi:10.1111/j.1600-0609.2004.00292.x

    authors: Franco V,Tripodo C,Rizzo A,Stella M,Florena AM

    更新日期:2004-09-01 00:00:00

  • Synchronous FIP1L1-PDGFRA-positive chronic eosinophilic leukemia and T-cell lymphoblastic lymphoma: a bilineal clonal malignancy.

    abstract::Several reports of successful empirical treatment of idiopathic hypereosinophilic syndrome with imatinib led to the recent identification of the FIP1L1-PDGFRA fusion gene rearrangement, which characterizes a distinctive group of chronic eosinophilic leukemias. This fusion gene can be detected in eosinophils, neutrophi...

    journal_title:European journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1600-0609.2007.00973.x

    authors: Capovilla M,Cayuela JM,Bilhou-Nabera C,Gardin C,Letestu R,Baran-Marzak F,Fenaux P,Martin A

    更新日期:2008-01-01 00:00:00

  • High-dose methylprednisolone for children with acute lymphoblastic leukemia and unfavorable presenting features.

    abstract::In an attempt to improve treatment outcome high-dose methylprednisolone (HDMP, 20-30 mg/kg, once a day orally) was used instead of a conventional dose of steroid (2 mg/kg/d, in 3 divided doses) in children with acute lymphoblastic leukemia (ALL) with increased risk factors. HDMP combined with cytotoxic agents (vincris...

    journal_title:European journal of haematology

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1600-0609.1997.tb01406.x

    authors: Hiçsönmez G,Gümrük F,Zamani PV,Tuncer MA,Yetgin S,Gürgey A,Atahan L,Ozsoylu S

    更新日期:1997-01-01 00:00:00

  • The prognostic significance of cytogenetic aberrations in childhood acute myeloid leukaemia. A study of the Swiss Paediatric Oncology Group (SPOG).

    abstract::In childhood-onset acute myeloid leukaemia (AML) the clinical value of karyotypic aberrations is now acknowledged, although there is still debate concerning the prognostic significance of some events. To add to this knowledge, cytogenetic analysis was performed on a consecutive series of 84 childhood AML patients diag...

    journal_title:European journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1600-0609.2007.00854.x

    authors: Betts DR,Ammann RA,Hirt A,Hengartner H,Beck-Popovic M,Kuhne T,Nobile L,Caflisch U,Wacker P,Niggli FK

    更新日期:2007-06-01 00:00:00

  • Is valganciclovir really effective in primary effusion lymphoma: case report of an HIV(-) EBV(-) HHV8(+) patient.

    abstract::Primary effusion lymphoma (PEL) is a human herpesvirus 8 (HHV8) associated lymphoproliferative disease characterized by effusions in body cavities, and lack of tumor mass. Valganciclovir is a treatment option in PEL, however, little is known about its clinical efficacy. Ganciclovir has been reported to be effective in...

    journal_title:European journal of haematology

    pub_type: 杂志文章

    doi:10.1111/ejh.12174

    authors: Ozbalak M,Tokatlı I,Özdemirli M,Tecimer T,Ar MC,Örnek S,Koroglu A,Laleli Y,Ferhanoglu B

    更新日期:2013-11-01 00:00:00

  • Induction of apoptosis in childhood acute leukemia by chemotherapeutic agents: failure to detect evidence of apoptosis in vivo.

    abstract::This study is designed to investigate whether apoptosis occurs in vivo in pediatric patients with acute leukemia during induction therapy. When patients with common acute lymphoblastic leukemia (cALL) and acute myeloblastic leukemia (AML) were treated with prednisolone (60 mg/m2/day, p.o. or i.v.) and etoposide (150 m...

    journal_title:European journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1600-0609.1994.tb01284.x

    authors: Matsubara K,Kubota M,Adachi S,Kuwakado K,Hirota H,Wakazono Y,Akiyama Y,Mikawa H

    更新日期:1994-01-01 00:00:00

  • Isolation and characterization of a tumor necrosis factor binding protein from urine.

    abstract::Tumor necrosis factor (TNF)/cachectin can produce both beneficial and harmful manifestations. Mechanisms may operate to counteract potentially harmful effects such as shock and cachexia. The TNF binding protein (TNF-BP), which is found at increased levels in serum and urine of patients with chronic renal failure, may ...

    journal_title:European journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1600-0609.1989.tb00111.x

    authors: Olsson I,Lantz M,Nilsson E,Peetre C,Thysell H,Grubb A,Adolf G

    更新日期:1989-03-01 00:00:00

  • Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response.

    abstract::Chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative neoplasm, characterized by persistent monocytosis. Due to the lack of unique surface markers expressed by neoplastic monocytes and the frequent CD34-negative blast immunophenotype, the diagnostic value of flow cytometric immunophenotyping (...

    journal_title:European journal of haematology

    pub_type: 杂志文章

    doi:10.1111/ejh.12477

    authors: Shen Q,Ouyang J,Tang G,Jabbour EJ,Garcia-Manero G,Routbort M,Konoplev S,Bueso-Ramos C,Medeiros LJ,Jorgensen JL,Wang SA

    更新日期:2015-08-01 00:00:00

  • Survival in adult acute lymphoblastic leukaemia (ALL): A report from the Swedish ALL Registry.

    abstract:OBJECTIVES:As new, effective therapies emerge for acute lymphoblastic leukaemia (ALL), the results of clinical trials need to relate to standard of care. METHODS:We used the population-based Swedish ALL Registry to evaluate characteristics, treatment and long-term outcome in 933 patients with diagnosis between 1997 an...

    journal_title:European journal of haematology

    pub_type: 杂志文章

    doi:10.1111/ejh.13247

    authors: Lennmyr E,Karlsson K,Ahlberg L,Garelius H,Hulegårdh E,Izarra AS,Joelsson J,Kozlowski P,Moicean A,Tomaszewska-Toporska B,Lübking A,Hallböök H,Swedish Adult Acute Lymphoblastic Leukaemia Group (SVALL).

    更新日期:2019-08-01 00:00:00

  • Clonal evolution in CLL patients as detected by FISH versus chromosome banding analysis, and its clinical significance.

    abstract::The acquisition of new aberrations during the course of chronic lymphocytic leukemia (CLL) named clonal evolution (CE) is usually detected by one of the two methods: chromosome banding analysis (CBA) and interphase fluorescence in situ hybridization (I-FISH). The purpose of this study was to compare the usefulness of ...

    journal_title:European journal of haematology

    pub_type: 杂志文章

    doi:10.1111/ejh.12215

    authors: Wawrzyniak E,Kotkowska A,Blonski JZ,Siemieniuk-Rys M,Ziolkowska E,Giannopoulos K,Robak T,Korycka-Wolowiec A

    更新日期:2014-02-01 00:00:00

  • Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a review.

    abstract::Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired disorder of the hematopoietic stem cell that makes blood cells more sensitive to the action of complement. Patients experience intravascular hemolysis, smooth muscle dystonia, renal failure, arterial and pulmonary hypertension, recurrent infectious diseases and ...

    journal_title:European journal of haematology

    pub_type: 杂志文章,评审

    doi:10.1111/ejh.12543

    authors: Devalet B,Mullier F,Chatelain B,Dogné JM,Chatelain C

    更新日期:2015-09-01 00:00:00

  • Long-term complication in follicular lymphoma: assessing the risk of secondary neoplasm in 242 patients treated or not with 90-yttrium-ibritumomab-tiuxetan.

    abstract:BACKGROUND:Non-Hodgkin lymphoma patients have a 25% increased risk of secondary primary neoplasms (SPNs). Regarding the controversy about the increased risk of SPN in patients exposed to radioimmunotherapy (RIT), we have analyzed this issue in a cohort of follicular lymphoma (FL) patients treated with/without RIT. PAT...

    journal_title:European journal of haematology

    pub_type: 杂志文章

    doi:10.1111/ejh.12775

    authors: Andrade-Campos MM,Liévano P,Espinosa-Lara N,Soro-Alcubierre G,Grasa-Ulrich JM,López-Gómez L,Baringo T,Giraldo P

    更新日期:2016-12-01 00:00:00

  • Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid (CC-4047) and their relationship with venous thrombosis.

    abstract::We evaluated the serum/plasma levels of cytokines [interleukin (IL)-6, vascular endothelial growth factor (VEGF), transforming growth factor (TGF)-beta2] and markers of coagulation, fibrinolysis, endothelial and platelet activation during the first 4 wk of treatment with the thalidomide analogue Actimid (CC-4047) in 1...

    journal_title:European journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1600-0609.2004.00393.x

    authors: Streetly M,Hunt BJ,Parmar K,Jones R,Zeldis J,Schey S

    更新日期:2005-04-01 00:00:00

  • Serum leptin levels in patients with idiopathic thrombocytopenic purpura.

    abstract:OBJECTIVES:The purpose of this study was to evaluate serum leptin levels in idiopathic thrombocytopenic purpura (ITP), in order to determine the influence of leptin on the pathogenesis of ITP. SUBJECTS AND METHODS:Forty-six untreated patients with chronic ITP were compared with 40 healthy people of similar age, sex an...

    journal_title:European journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1600-0609.2004.00231.x

    authors: Zhan M,Zhao H,Yang R,Han ZC

    更新日期:2004-05-01 00:00:00

  • Cytoskeletal regulation of chemotactic receptors: molecular complexation of N-formyl peptide receptors with G proteins and actin.

    abstract::Signal transduction via receptors for N-formylmethionyl peptide chemoattractants (FPR) on human neutrophils is a highly regulated process. It involves direct interaction of receptors with heterotrimeric G-proteins and may be under the control of cytoskeletal elements. Evidence exists suggesting that the cytoskeleton a...

    journal_title:European journal of haematology

    pub_type: 杂志文章,评审

    doi:10.1111/j.1600-0609.1993.tb01610.x

    authors: Jesaitis AJ,Klotz KN

    更新日期:1993-11-01 00:00:00

  • Cost-effectiveness of rituximab as maintenance treatment for relapsed follicular lymphoma: results of a population-based study.

    abstract:OBJECTIVES:On the basis of two population-based registries, our study aims to calculate the real-world cost-effectiveness of rituximab maintenance compared with observation in relapsed or refractory follicular lymphoma patients who responded to second-line chemotherapy. METHODS:Data were obtained from the EORTC20981 t...

    journal_title:European journal of haematology

    pub_type: 杂志文章

    doi:10.1111/ejh.12264

    authors: Blommestein HM,Issa DE,Pompen M,Ten Hoor G,Hogendoorn M,Joosten P,Zweegman S,Huijgens PC,Uyl-de Groot CA

    更新日期:2014-01-01 00:00:00

  • Labelling autologous platelets with 111In tropolonate for platelet kinetic studies: limitations imposed by thrombocytopenia.

    abstract::An in vitro method of radiolabelling platelets with 111In tropolonate in plasma has been devised enabling imaging and cell kinetic studies to be performed in patients with thrombocytopenia (TP) using autologous, rather than donor, platelets. Platelets from 10 TP patients, with platelet counts ranging from 4-91 x 10(9)...

    journal_title:European journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1600-0609.1990.tb00461.x

    authors: Danpure HJ,Osman S,Peters AM

    更新日期:1990-10-01 00:00:00

  • Drug-induced skin reactions in patients with acute non-lymphocytic leukaemia.

    abstract::The incidence of drug-induced skin rashes and related factors were analysed in a retrospective study of 151 patients with acute non-lymphocytic leukaemia (ANLL). 91 (60%) developed a drug-related toxicodermia to one or more drugs during remission, induction and maintenance therapy. The incidence of rashes was mainly c...

    journal_title:European journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1600-0609.1987.tb01168.x

    authors: Verhagen C,Stalpers LJ,de Pauw BE,Haanen C

    更新日期:1987-03-01 00:00:00

  • BAALC and WT1 expressions from diagnosis to hematopoietic stem cell transplantation: consecutive monitoring in adult patients with core-binding-factor-positive AML.

    abstract::No consecutive analysis of BAALC and WT1 expressions associated with core-binding factor AML (CBF-AML) from diagnosis to hematopoietic stem cell transplantation (HSCT) has yet been reported. We investigated BAALC and WT1 expressions using a method of real-time quantitative polymerase chain reaction (RQ-PCR) at diagnos...

    journal_title:European journal of haematology

    pub_type: 杂志文章

    doi:10.1111/ejh.12142

    authors: Yoon JH,Kim HJ,Shin SH,Yahng SA,Lee SE,Cho BS,Eom KS,Kim YJ,Lee S,Min CK,Cho SG,Kim DW,Lee JW,Min WS,Park CW,Lim JH

    更新日期:2013-08-01 00:00:00

  • Targeting of cell metabolism in human acute myeloid leukemia--more than targeting of isocitrate dehydrogenase mutations and PI3K/AKT/mTOR signaling?

    abstract::Targeting of cellular metabolism has emerged as a possible strategy in the treatment of human malignancies, and several experimental studies suggest that this therapeutic approach should also be considered in acute myeloid leukemia (AML). Clinical studies of metabolic intervention in AML patients with isocitrate dehyd...

    journal_title:European journal of haematology

    pub_type: 杂志文章,评审

    doi:10.1111/ejh.12690

    authors: Hauge M,Bruserud Ø,Hatfield KJ

    更新日期:2016-03-01 00:00:00

  • Successful interim therapy with imatinib prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute myeloid leukemia.

    abstract:OBJECTIVES:Imatinib (Glivec, STI571) has been successfully used in patients with chronic myelogenous leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome (Ph). We used imatinib interim therapy for four consecutive patients with newly diagnosed Ph+ acute myeloid leukemia (AML). We monitored the pat...

    journal_title:European journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1600-0609.2007.00890.x

    authors: Cho BS,Kim HJ,Lee S,Eom KS,Min WS,Lee JW,Kim CC

    更新日期:2007-08-01 00:00:00

  • Chromosome abnormalities defined by conventional cytogenetics in plasma cell leukemia: what have we learned about its biology?

    abstract::Cancer cells are characterized by having chromosomal abnormalities. The number of aberrations and the specific chromosomes affected are likely correlated with tumor progression. In this study, we analyzed the karyotype of 126 plasma cell leukemia (PCL) patients to identify the most frequently occurring imbalances and ...

    journal_title:European journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1600-0609.2011.01629.x

    authors: Jimenez-Zepeda VH,Neme-Yunes Y,Braggio E

    更新日期:2011-07-01 00:00:00

  • Engraftment of human myelodysplastic syndrome derived cell line in transgenic severe combined immunodeficient (TG-SCID) mice expressing human GM-CSF and IL-3.

    abstract::A transgenic SCID (TG-SCID) mouse expressing the human cytokines interleukin-3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF) has been generated with the aim of making a model system allowing the in vivo proliferation of human hematopoietic cells. Using TG-SCID mice expressing high levels (30-35 ...

    journal_title:European journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1600-0609.1998.tb01067.x

    authors: Kim DK,Kojima M,Fukushima T,Miyasaka M,Nakauchi H

    更新日期:1998-08-01 00:00:00

  • P53 deletion may drive the clinical evolution and treatment response in multiple myeloma.

    abstract::We report a patient with multiple myeloma presenting with a paraspinal plasmacytoma with a marked dissociation between the response obtained in bone marrow (BM) infiltration and that achieved in soft tissue masses. While a complete remission was reached and maintained in BM, extramedullary plasmacytomas were refractor...

    journal_title:European journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1600-0609.2009.01399.x

    authors: López-Anglada L,Gutiérrez NC,García JL,Mateos MV,Flores T,San Miguel JF

    更新日期:2010-04-01 00:00:00

  • Use of splenic volume estimation to distinguish primary thrombocythaemia from reactive thrombocytosis.

    abstract::Splenic volume was measured by visual assessment of planar images of the spleen, and also by single photon emission computerised tomography (SPECT) using 99mtechnetium tin colloid, in a group of 33 patients with primary thrombocythaemia (PT) or reactive thrombocytosis. Volumes greater than 337 cm3 correlated strongly ...

    journal_title:European journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1600-0609.1988.tb00188.x

    authors: Messinezy M,Chapman R,Dudley JM,Nunan TO,Pearson TC

    更新日期:1988-04-01 00:00:00

  • Quantification of progenitors capable of generating T cells in human cord blood.

    abstract:OBJECTIVE:For transplantation of cord blood (CB) cells, it is important to select a CB sample that can reconstitute not only myelo-erythropoiesis but also lymphopoiesis in recipients. However, until now the reconstitution ability of CB samples has been assessed by colony forming unit-culture (CFU-C) assay or by simply ...

    journal_title:European journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1600-0609.2007.00991.x

    authors: Kato M,Masuda K,Kakugawa K,Kawamoto H,Mugishima H,Katsura Y

    更新日期:2008-02-01 00:00:00

  • Cost analysis of CHOP (-like) chemotherapy regimens for patients with newly diagnosed aggressive non-Hodgkin's lymphoma.

    abstract::Many cost analyses of stem-cell transplantations are available, which is in sharp contrast to the level of cost analyses on first-line chemotherapy for aggressive non-Hodgkin's lymphoma (NHL). Given the scarcity of cost analyses of first-line chemotherapy for NHL, it is difficult to assess the economic impact of upcom...

    journal_title:European journal of haematology

    pub_type: 杂志文章

    doi:10.1034/j.1600-0609.2002.02772.x

    authors: van Agthoven M,Faber LM,Uyl-de Groot CA,Sonneveld P,Verdonck LF,Willemze R,Kluin-Nelemans JC,Löwenberg B,Huijgens PC

    更新日期:2002-10-01 00:00:00

  • Interleukin-17 enhances the production of interferon-γ and tumour necrosis factor-α by bone marrow T lymphocytes from patients with lower risk myelodysplastic syndromes.

    abstract:INTRODUCTION:Lower risk myelodysplastic syndromes (MDSs) are characterised by increased apoptosis of haematopoietic cells in the bone marrow (BM). The mechanism driving this excessive apoptosis involves multiple immune molecules, including inflammatory cytokines such as interferon-γ (IFN-γ), tumour necrosis factor-α (T...

    journal_title:European journal of haematology

    pub_type: 杂志文章

    doi:10.1111/ejh.12074

    authors: Zhang Z,Li X,Guo J,Xu F,He Q,Zhao Y,Yang Y,Gu S,Zhang Y,Wu L,Chang C

    更新日期:2013-05-01 00:00:00

  • Analysis of CD34-positive cells in bone marrow from patients with myelodysplastic syndromes and acute myeloid leukemia and in normal individuals: a comparison between FACS analysis and immunohistochemistry.

    abstract::In patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), expression of the hematopoietic stem cell marker CD34 has been associated with a poorer prognosis. CD34 is usually analyzed by flow cytometry (FC), but may also be analyzed using immunohistochemistry (IH). The present study was undertak...

    journal_title:European journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1600-0609.1996.tb01330.x

    authors: Kanter-Lewensohn L,Hellström-Lindberg E,Kock Y,Elmhorn-Rosenborg A,Ost A

    更新日期:1996-03-01 00:00:00

  • Refractoriness to alpha-interferon (Intron A) in previously chemotherapy-treated patients with chronic myelocytic leukaemia.

    abstract::8 patients with chronic myeloid leukaemia in the chronic phase who had previously received chemotherapy were given alpha-interferon (Intron A). The Intron A was administered subcutaneously at a dose of 2 x 10(6) I.U./m2 three times a week and this was increased to 4-5 million I.U./m2 daily if no response was obtained ...

    journal_title:European journal of haematology

    pub_type: 杂志文章

    doi:10.1111/j.1600-0609.1988.tb00182.x

    authors: Friche E,Hansen MM,Wieslander S

    更新日期:1988-04-01 00:00:00